SCHEMBL6440860

SCHEMBL6440860

COC(=O)c1n[nH]nc1C(=O)OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
KDM4C Q9H3R0 1/20 0.52
KDM4E B2RXH2 3/20 0.46
STAT3 P40763 1/20 0.46
HIF1A Q16665 1/20 0.46
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 1/20 0.38
TSHR P16473 2/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 2/20 0.35
F2 P00734 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
ERCC1 P07992 1/20 0.35
FEN1 P39748 1/20 0.35
ERCC4 Q92889 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440864 0.91 SMN1; SMN2 (0.56) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL7229858 0.89 SMN1; SMN2 (0.50) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL1412516 0.86 SMN1; SMN2 (0.51) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL31436306 0.84 SMN1; SMN2 (0.50) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL17627087 0.84 SMN1; SMN2 (0.50) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL8951086 0.75 NPSR1 (1.00) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL1256960 0.73 SMN1; SMN2 (0.72) SMN1; SMN2KDM4EALDH1A1L3MBTL1LMNA
SCHEMBL5761874 0.70 NPSR1 (0.48) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL16453474 0.70 KDM4C (0.53) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL19763311 0.70 KDM4C (0.48) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301284-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-05-28 US disclosed
EP-1539717-A2 MICROBIOCIDAL (E.G FUNGICIDAL) 1,2,3-TRIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2005-06-15 EP disclosed
WO-2004018438-A2 MICROBIOCIDAL (E.G. FUNGICIDAL) 1,2,3-TRIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301284-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 NPSR1 1946/4885SMN1; SMN2 4577/4885KDM4C 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.